NeuroSense Therapeutics Ltd.
NRSNW
NASDAQ Capital Market0.08
USD
-0.02
- -
CIK
0001875091
ISIN
IL0011811630
CUSIP
M74240116
Return %
Stock
S&P500
1Y
-89.31
19.01
3Y
-56.16
65.48
5Y
-91.97
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Alon Ben-Noon
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Medinat ha-Yehudim Street 85 Herzliya TA Israel 4676670
- IPO Date
- Dec 9, 2021
- CIK
- 0001875091
- Website
- neurosense-tx.com
- Similar Companies
- Business
- NeuroSense Therapeutics Ltd. (NRSNW) is a clinical-stage biotechnology company focused on discovering and developing targeted therapeutics for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease. The company offers PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib targeting microRNA dysregulation, iron accumulation and neuroinflammation in ALS and granted orphan drug designation by the FDA and EMA; CogniC, a combination drug addressing inflammation, oxidative stress and amyloid-β aggregation in Alzheimer's disease currently enrolling in a Phase 2 RoAD trial (NCT06185543); and StabiliC, a preclinical candidate for Parkinson's disease. NeuroSense Therapeutics operates primarily in the United States, Canada, Israel, Italy and internationally from its headquarters in Herzliya, Israel, where it was founded in 2017. Recent developments include entering a binding term sheet in December 2024 with a major global pharmaceutical partner for PrimeC development and commercialization in key markets with a definitive agreement anticipated in 2025; regaining Nasdaq stockholders' equity compliance in January 2025 following a $5 million private placement; reporting additional Phase 2b PARADIGM study data in February 2025 showing 40% slower functional decline and 74% improved survival in adherent patients; presenting biomarker data at the American Academy of Neurology in April 2025; scaling PrimeC manufacturing to commercial levels with a global CDMO in May 2025; completing a $500,000 private placement at a 40% market premium in September 2025; and preparing for a multinational Phase 3 ALS trial and new NOC/c submission to Health Canada in the second half of 2025.
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December